M&A Deal Summary

Epirus Biopharmaceuticals Acquires Zalicus

On July 15, 2014, Epirus Biopharmaceuticals acquired life science company Zalicus

Acquisition Highlights
  • This is Epirus Biopharmaceuticals’ 1st transaction in the Life Science sector.
  • This is Epirus Biopharmaceuticals’ 1st transaction in the United States.
  • This is Epirus Biopharmaceuticals’ 1st transaction in Massachusetts.

M&A Deal Summary
Date 2014-07-15
Target Zalicus
Sector Life Science
Buyer(s) Epirus Biopharmaceuticals
Deal Type Merger
Advisor(s) Wedbush Securities, Inc. (Financial)
Goodwin Procter (Legal)

Target

Zalicus

Cambridge, Massachusetts, United States
Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and inflammation.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Epirus Biopharmaceuticals

Boston, Massachusetts, United States
Category Company
Founded 2011
Sector Life Science
Employees73
DESCRIPTION

Epirus Biopharmaceuticals is a biopharmaceutical company, develops, manufactures and commercializes biosimilar therapeutics worldwide. Epirus Biopharmaceuticals is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Merger) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2014) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-09-09 Bioceros BV

Utrecht, Netherlands

Bioceros BV is a biopharmaceutical R&D company focused on the development of mAbs and generation of GMP-ready cell lines. Over the past decade, Bioceros has developed numerous biosimilar cell lines from its proprietary, well-characterized CHO platform (CHOBC®)i.

Buy $14M
Mergr

Product

Company

Legal